RT Journal Article
SR Electronic
T1 Impact of vaccination on new SARS-CoV-2 infections in the UK
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.04.22.21255913
DO 10.1101/2021.04.22.21255913
A1 Pritchard, Emma
A1 Matthews, Philippa C.
A1 Stoesser, Nicole
A1 Eyre, David W.
A1 Gethings, Owen
A1 Vihta, Karina-Doris
A1 Jones, Joel
A1 House, Thomas
A1 VanSteenHouse, Harper
A1 Bell, Iain
A1 Bell, John I
A1 Newton, John N
A1 Farrar, Jeremy
A1 Diamond, Ian
A1 Rourke, Emma
A1 Studley, Ruth
A1 Crook, Derrick
A1 Peto, Tim
A1 Walker, A. Sarah
A1 Pouwels, Koen B.
YR 2021
UL http://medrxiv.org/content/early/2021/06/09/2021.04.22.21255913.abstract
AB The effectiveness of COVID-19 vaccination in preventing new SARS-CoV-2 infections in the general community is still unclear. Here, we used the Office for National Statistics (ONS) COVID-19 Infection Survey, a large community-based survey of individuals living in randomly selected private households across the UK, to assess the effectiveness of BNT162b2 (Pfizer-BioNTech) and ChAdOx1 nCoV-19 (Oxford-AstraZeneca; ChAdOx1) vaccines against any new SARS-CoV-2 PCR-positive tests, split according to self-reported symptoms, cycle threshold value (<30 versus ≥30) as a surrogate for viral load, and gene positivity pattern (compatible with B.1.1.7 or not). Using 1,945,071 RT-PCR results from nose and throat swabs taken from 383,812 participants between 1 December 2020 and 8 May 2021, we found that vaccination with the ChAdOx1 or BNT162b2 vaccines already reduced SARS-CoV-2 infections ≥21 days after the first dose (61%, 95% CI 54 to 68% versus 66%, 95% CI 60 to 71%, respectively) with greater reductions observed after a second dose (79%, 95% CI 65 to 88% versus 80%, 95% CI 73 to 85%, respectively). Largest reductions were observed for symptomatic infections and/or infections with a higher viral burden. Overall, COVID-19 vaccination reduced the number of new SARS-CoV-2 infections, with the largest benefit received after two vaccinations and against symptomatic and high viral burden infections, and with no evidence of difference between the BNT162b2 and ChAdOx1 vaccines.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure from at www.icmje.org/coi_disclore.pdf and declare: DWE declares lecture fees from Gilead, outside the submitted work; EP, PCM, NS, DWE, JIB, DC, TEAP, ASW, and KBP are employees of the University of Oxford, but not involved in the development or production of the vaccine; JIB act as an unpaid advisor to HMG on Covid but does not sit on the vaccine task force and it not involved in procurement decisions, sits on the Board of OSI who has an investment in Vaccitech who have a royalty from the ChAdOx1 vaccine when, if ever, it makes a profit; HVS reports personal fees from BioSpyder Technologies, Inc, outside the submitted work; ASW besides funding mentioned above, also received grants from Medical Research Council UK during the conduct of the study; there are no other relationships or activities that could appear to have influenced the submitted work.Clinical TrialISRCTN21086382.Clinical Protocols https://www.ndm.ox.ac.uk/covid-19/covid-19-infection-survey/protocol-and-information-sheets Funding StatementThis study is funded by the Department of Health and Social Care with in-kind support from the Welsh Government, the Department of Health on behalf of the Northern Ireland Government and the Scottish Government. EP, KBP, ASW, TEAP, NS, DE are supported by the National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). ASW and TEAP are also supported by the NIHR Oxford Biomedical Research Centre. EP and KBP are also supported by the Huo Family Foundation. ASW is also supported by core support from the Medical Research Council UK to the MRC Clinical Trials Unit [MC_UU_12023/22] and is an NIHR Senior Investigator. PCM is funded by Wellcome (intermediate fellowship, grant ref 110110/Z/15/Z) and holds an NIHR Oxford BRC Senior Fellowship award. DWE is supported by a Robertson Fellowship and an NIHR Oxford BRC Senior Fellowship. The views expressed are those of the authors and not necessarily those of the National Health Service, NIHR, Department of Health, or PHE. The funder/sponsor did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. All authors had full access to all data analysis outputs (reports and tables) and take responsibility for their integrity and accuracy. We are grateful for the support of all COVID-19 Infection Survey participants and the COVID-19 Infection Survey team. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study received ethical approval from the South Central Berkshire B Research Ethics Committee (20/SC/0195).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are still being collected for the COVID-19 Infection Survey. De-identified study data are available for access by accredited researchers in the ONS Secure Research Service (SRS) for accredited research purposes under part 5, chapter 5 of the Digital Economy Act 2017. For further information about accreditation, contact Research.Support{at}ons.gov.uk or visit the SRS website.